Navigation Links
Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis
Date:4/21/2008

WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its development partner, BioAlliance Pharma reported preliminary, top-line results for a Phase III study of Loramyc(R) (miconazole Lauriad(R)) mucoadhesive buccal tablets, in the treatment of oropharyngeal candidiasis (OPC).

Top line data show that Loramyc(R) achieved its primary endpoint of noninferiority to Mycelex(R) Troche (clotrimazole)* in the complete resolution of signs and symptoms of OPC (complete clinical cure). The randomized, double-blind, double-dummy study was conducted in 577 HIV-positive patients in 40 sites in the United States, Canada, and South Africa. All secondary endpoints were also met.

Loramyc(R), which is approved in Europe and currently being marketed in France, is an antifungal delivered in a mucoadhesive buccal tablet designed to enable local once-daily dosing of the active ingredient at the site of infection.

In July 2007, Par Pharmaceutical, Inc. entered into an exclusive licensing agreement under which Par received commercialization rights in the U.S. to BioAlliance Pharma's Loramyc(R) (miconazole Lauriad(R)). In return for the commercialization rights to Loramyc(R), Par paid BioAlliance an initial payment of $15 million, which Par incurred as a research and development (R&D) expense in 2007. Upon FDA approval of the product, Par will also pay BioAlliance $20 million. In addition to royalties on sales, BioAlliance may receive milestone payments on future sales.

John MacPhee, president of Strativa Pharmaceuticals, said, "We are pleased with the results of this trial. There is a significant need fo
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
2. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
5. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
6. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
7. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
8. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
9. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
10. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
11. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... , Sept. 29, 2014 Pharmaceutical Care Management ... today outlined policy solutions that could reduce prescription fraud ... Hill briefing, " Prescription Opioid Abuse: Fighting Back on ... Reform and PCMA. The briefing featured ... prescription drug abuse and fraud. The Centers for Disease ...
(Date:9/29/2014)... , Sept. 29, 2014 EU5 Sigmoidoscopes ... new report, "EU5 Sigmoidoscopes Market Outlook to 2020", ... market. The report provides value, in millions of ... (in US dollars) within market segments - Flexible ... and Flexible Non-Video (Fibre) Sigmoidoscopes). The ...
(Date:9/29/2014)... SAN DIEGO , 29 de septiembre de 2014 ... adelante, Daiichi Sankyo) (TSE: 4568) y Ambit Biosciences (NASDAQ: ... que han llegado a un acuerdo de fusión definitivo ... acciones ordinarias de Ambit Biosciences a un precio de ... una oferta de licitación seguida de una fusión con ...
Breaking Medicine Technology:PCMA: How Congress Can Fight Prescription Drug Fraud and Abuse 2EU5 Sigmoidoscopes Market Outlook to 2020 2EU5 Sigmoidoscopes Market Outlook to 2020 3Daiichi Sankyo adquiere Ambit Biosciences 2Daiichi Sankyo adquiere Ambit Biosciences 3Daiichi Sankyo adquiere Ambit Biosciences 4Daiichi Sankyo adquiere Ambit Biosciences 5Daiichi Sankyo adquiere Ambit Biosciences 6Daiichi Sankyo adquiere Ambit Biosciences 7Daiichi Sankyo adquiere Ambit Biosciences 8
... safety profile of BSI-201 in ... subjects with advanced solid tumors -, BRISBANE, Calif., ... developing novel cancer therapies,today announced that data supporting its lead ... of Clinical Oncology annual,meeting in Chicago., Findings will be ...
... SGP ), a leader in advancing the ... infection, announced today that data from,several clinical studies ... therapy, as well as boceprevir, the,company,s investigational oral ... annual Digestive Disease Week (DDW) meeting to be ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 ... now offering gum depigmentation treatments for dark gums. Dark ... can make people feel extremely self-conscious about their smiles. ... or dark gums. “I am one of the few ... and I have treated celebrities, business leaders, high-ranking officials ...
(Date:9/30/2014)... In books and movies, plots involving older men chasing ... suggests that the stereotype may be grounded in fact. ... than 12,000 people from Finland. The researchers, led by ... women typically preferred men who were the same age or ... On the other hand, men tended to have a lifelong ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- For millions of ... excess weight and the threat of type 2 diabetes. ... may be tougher for some than for others, depending ... good health, it may not be as effective for ... 2 diabetes," said one expert, Dr. Ruth Loos, director ...
(Date:9/30/2014)... University of Michigan have described a new approach to ... the time needed for more traditional methods. , ... that is undergoing further investigation as a potential treatment ... , In research published online in the Proceedings ... the lab of Stephen Weiss at the U-M Life ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Dr. Alex Farnoosh, is Now Offering Gum Depigmentation for Dark Gums 2Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:New discovery approach accelerates identification of potential cancer treatments 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2
... men has increased by 12% in six years, according to the ... diagnosed with the disease, 3,000 of those are men.// ... that they tend to occur more commonly on the back, whereas ... noticeable. Up to 77% of cases are caused by exposure to ...
... a mother's risk of having a hyperactive child. A ... the last three months of pregnancy had children with ... Glover, of Imperial College, London, told that this only ... frequently feeling scared.According to a survey antenatal anxiety ...
... somebody is likely to have an epileptic seizure. ,In ... warning and can lead to ,disability or even death. ... believe ,it may be possible to predict the onset ... ,An ECG records electrical activity from different parts of ...
... years. And while most of the popular remedies used in ... has increased. This powerful pill will //reduce pain, fever, inflammation, ... attacks and stroke. ,In the more than 35 ... few drugs have been developed that can even be compared ...
... one day have the option of having one blast ... up to 25 sessions afterwards, researchers said. //They believe ... for women and may improve the treatment of breast ... the developing world. ,Dr. Emiel Rutgers, of the ...
... new compounds developed for preventing and treating the flue ... only one dose to be effective.// The compounds, known ... flu drug relenza, or zanamivir, which the U.S. Food ... A and B. ,Researchers reported at the International ...
Cached Medicine News:
The 5539-7.5 linear transducer is a high frequency transducer dedicated to superficial and vascular imaging....
HST, versatile convex array abdominal transducer is multi-frequency, offering 5 levels of fundamental frequencies in addition to 4 settings of Harmonic frequencies. This transducer provides superb im...
Scan internal organs percutaneously while eliminating side lobe artifact....
... transducer is a curved ... the higher frequencies. Featuring ... this transducer provides exceptional ... frequency abdominal kidney bladder ...
Medicine Products: